Labcorp to Acquire BioReference Assets From OPKO for $872M
Labcorp agreed to acquire OPKO Health's remaining BioReference Health assets for up to $872M, including clinical diagnostics and the 4Kscore prostate cancer test. OPKO shares rose 20% premarket. The deal follows prior acquisitions of BioReference units, allowing OPKO to focus on biopharmaceuticals. Labcorp expects the acquired businesses to generate $250M in annual revenue.
How this was made
The 30-second read
Why it matters
The transaction reshapes the U.S. diagnostic testing landscape, providing Labcorp with scale and OPKO with cash for its biopharma pipeline.
Market read
First‑report M&A deal of $872M, materially affecting both companies and the broader diagnostics sector.
What to watch
Regulatory clearance risk and potential earn‑out contingent on 4Kscore performance may delay full benefits.
Background
Labcorp and OPKO Health have been gradually unwinding their relationship over three years, culminating in this final asset sale.
Ticker impact
Labcorp announced a $872M acquisition of OPKO's BioReference assets, a material M&A deal expanding its diagnostics business.
likely upward pressure as investors price in revenue growth and scale synergies
Large‑scale deal, first disclosure, and clear revenue upside drive a bullish reaction.
Market effects
Consolidation in the clinical diagnostics sector may pressure peers' valuations.
U.S. healthcare and biotech markets see increased M&A activity expectations.
Large U.S. lab operator expansion could influence global diagnostic service pricing.
Counterpoint
If integration costs exceed expectations, the deal could become a value destroyer for Labcorp.
Key entities
- CompanyLabcorp
U.S. clinical laboratory services provider (ticker LH).
- CompanyOPKO Health
Biopharma company (ticker OPKO) selling its diagnostic unit.
